These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31431290)

  • 1. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
    Igbinosa O; Dogho P; Osadiaye N
    Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
    Li C; Li Y; Zhao Z; Liu Q; Li B
    J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
    Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUropean prospective cohort study on
    Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
    BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
    Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
    Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
    BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem-resistant
    Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
    Front Public Health; 2022; 10():983174. PubMed ID: 36091556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
    Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
    J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cohort Study of the Impact of Carbapenem-Resistant
    Sabino S; Soares S; Ramos F; Moretti M; Zavascki AP; Rigatto MH
    mSphere; 2019 Apr; 4(2):. PubMed ID: 30971443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential for Interventions in a Long-term Acute Care Hospital to Reduce Transmission of Carbapenem-Resistant Enterobacteriaceae in Affiliated Healthcare Facilities.
    Toth DJA; Khader K; Slayton RB; Kallen AJ; Gundlapalli AV; O'Hagan JJ; Fiore AE; Rubin MA; Jernigan JA; Samore MH
    Clin Infect Dis; 2017 Aug; 65(4):581-587. PubMed ID: 28472233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
    Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
    Lim CL; Spelman D
    Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
    Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
    Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
    BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Antimicrob Resist Infect Control; 2017; 6():124. PubMed ID: 29225798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.